Yep, maybe a little something related to equivalency along the way and Merck sending in someone to take a peek to figure out valuation based on a way to hit the ground running towards meeting expected demand, label extension and potential expanded production site capacity as needed. I think Mr. Duffy's boss might be interested in that line of thinking : ). Best wishes.
News 
Market Data 
Discover 
AI
